The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
Bayer AG has posted a reasonable set of financials for the fourth quarter but done little to assuage concerns about how the German major intends to replenish its pipeline.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
